NCT06956170 - All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 10, 2022

Primary Completion Date

May 27, 2024

Study Completion Date

November 30, 2029

Conditions

Multiple Myeloma

Interventions

DRUG

Belantamab mafodotin

Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate will be administered.

DRUG

Pomalidomide

Immunomodulatory drug (IMiD) will be administered.

DRUG

Dexamethasone

Synthetic glucocorticoid with anti-tumor activity will be administered.

DRUG

Bortezomib

Proteasome Inhibitor will be administered.

Trial Locations (13)

467-8602

GSK Investigational Site, Nagoya

296-8602

GSK Investigational Site, Kamogawa

277-8567

GSK Investigational Site, Kashiwa

790-8524

GSK Investigational Site, Matsuyama

960-1295

GSK Investigation Site, Fukushima

371-8511

GSK Investigational Site, Maebashi

377-0280

GSK Investigational Site, Shibukawa

028-3695

GSK Investigational Site, Numakunai

701-1192

GSK Investigational Site, Okayama

565-0871

GSK Investigational Site, Osaka

683-8504

GSK Investigational Site, Tottori-shi

990-9585

GSK Investigational Site, Yamagata

060-8648

GSK Investigational Site, Hokkaido